Compare BRTX & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | VIVS |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.8M |
| IPO Year | 2015 | 2010 |
| Metric | BRTX | VIVS |
|---|---|---|
| Price | $2.31 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 169.5K | ★ 549.8K |
| Earning Date | 05-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $4,603,000.00 |
| Revenue This Year | $298.39 | $42.38 |
| Revenue Next Year | $64.62 | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.82 |
| 52 Week Low | $0.14 | $0.21 |
| 52 Week High | $4.10 | $3.54 |
| Indicator | BRTX | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 27.63 |
| Support Level | $0.22 | N/A |
| Resistance Level | $2.93 | $0.30 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 2.35 | 1.89 |
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.